NAD+ Precursors for Neurodegeneration

NAD+ Precursors for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">NAD+ Precursors for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>335.22</td>
</tr>
<tr>
<td class="label">Brain delivery</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Dose range studied</td>
<td>100-500 mg</td>
</tr>
<tr>
<td class="label">Clinical trial evidence</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">CBS/PSP-specific data</td>
<td>None</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>High</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT02975239 (NADINE)</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">NCT03432879</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT03151239</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT05174485 (CHROME-NR)</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT04034438</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">NCT05394025</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">NCT05578164</td>
<td>Phase 2</td>
</tr>
</table>

NAD+ Precursors for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">NAD+ Precursors for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>335.22</td>
</tr>
<tr>
<td class="label">Brain delivery</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Dose range studied</td>
<td>100-500 mg</td>
</tr>
<tr>
<td class="label">Clinical trial evidence</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">CBS/PSP-specific data</td>
<td>None</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>High</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT02975239 (NADINE)</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">NCT03432879</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT03151239</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT05174485 (CHROME-NR)</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT04034438</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">NCT05394025</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">NCT05578164</td>
<td>Phase 2</td>
</tr>
</table>

NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme found in all living cells, serving as a critical regulator of cellular metabolism, energy production, DNA repair, and signaling pathways[@cant2015]. During normal aging, NAD+ levels decline progressively in multiple tissues, including the brain—a phenomenon that has been strongly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and the tauopathies corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP)[@lautrup2019]. This decline compromises the function of NAD+-dependent enzymes, particularly the sirtuins, poly(ADP-ribose) polymerases (PARPs), and CD38/CD157 ectoenzymes, leading to mitochondrial dysfunction, impaired DNA repair, and chronic neuroinflammation[@aman2018].

NAD+ precursor therapy involves supplementation with compounds that serve as substrates for cellular NAD+ biosynthesis, thereby replenishing declining NAD+ stores and restoring the function of NAD+-dependent processes[@yoshino2018]. The most extensively studied NAD+ precursors include nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and nicotinamide (NAM), each with distinct pharmacokinetic properties and clinical evidence profiles[@poddar2019]. This monograph provides a comprehensive evidence synthesis of NAD+ precursor therapy for neurodegenerative diseases, with specific attention to CBS and PSP where evidence exists.

The NAD+ Depletion Hypothesis in Neurodegeneration

Age-Related NAD+ Decline

The concentration of NAD+ in human brain tissue declines approximately 50% between ages 40 and 80, with some studies reporting even steeper declines in specific brain regions affected by neurodegeneration[@zhu2015]. This decline is attributable to multiple mechanisms:

Consequences for Neurodegenerative Diseases

The downstream effects of NAD+ depletion are particularly relevant to the proteinopathies characteristic of CBS and PSP:

Mitochondrial dysfunction: NAD+ is essential for mitochondrial respiration through its role as an electron carrier in the electron transport chain. Reduced NAD+ impairs Complex I activity, decreases ATP production, and increases [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) generation—mechanisms central to both tau and [α-synuclein](/proteins/alpha-synuclein) pathology[@karuppagounder2012].

DNA repair impairment: PARP1 and PARP2 consume NAD+ during DNA repair, and PARP hyperactivation (as occurs in response to increased DNA damage in aging neurons) can paradoxically deplete NAD+ stores, creating a vicious cycle of genomic instability[@wang2018].

Sirtuin dysfunction: The sirtuin family (SIRT1-7) requires NAD+ as a cofactor for deacetylase activity. SIRT1 activation promotes tau deacetylation and [autophagy](/entities/autophagy); SIRT3 regulates mitochondrial protein acetylation and antioxidant defenses. NAD+ depletion impairs these protective functions[@procaccio2014].

Neuroinflammation: NAD+ metabolism intersects with the innate immune system through multiple pathways. The NAD+-CD38-cADPR axis regulates calcium signaling in immune cells, and NAD+ depletion promotes pro-inflammatory microglial activation[@galla2020].

NAD+ Biosynthetic Pathways

The Salvage Pathway

The predominant NAD+ biosynthetic pathway in mammalian cells is the salvage pathway, which recycles nicotinamide (a byproduct of NAD+-consuming reactions) back into NAD+[@houtkooper2010]:

Nicotinamide → (NAMPT) → Nicotinamide Mononucleotide (NMN) → (NMNAT) → NAD+

This pathway consists of two enzymatic steps catalyzed by:

• NAMPT (nicotinamide phosphoribosyltransferase): Rate-limiting enzyme that converts nicotinamide to NMN[@revollo2004]
• NMNAT (nicotinamide mononucleotide adenylyltransferase): Converts NMN to NAD+ using ATP[@berger2005]

Alternative Biosynthetic Routes

The Preiss-Handler pathway uses dietary nicotinic acid (niacin) as a precursor, through the actions of nicotinic acid phosphoribosyltransferase (NAPRT) and NMNATs[@hara2007].

De novo synthesis from tryptophan is primarily active in the liver and represents a minor source of NAD+ in the brain under normal conditions[@bogan2008].

The NR Pathway

Nicotinamide riboside (NR) enters the NAD+ salvage pathway via a distinct route:
NR → (NRK) → NMN → (NMNAT) → NAD+

The enzyme nicotinamide riboside kinase (NRK) phosphorylates NR to form NMN, bypassing the NAMPT-mediated step[@bieganowski2004]. This may provide therapeutic advantages in conditions where NAMPT activity is compromised.

Key NAD+ Precursors

Nicotinamide Mononucleotide (NMN)

Chemistry and pharmacokinetics: NMN is a nucleotide composed of nicotinamide, ribose, and phosphate (C11H15N2O8P, MW 335.22 Da)[@mills2016]. NMN is transported into cells via specific transporters, including SLC12A8 (a sodium-coupled monocarboxylate transporter) expressed in the small intestine and other tissues[@grozio2019]. Oral NMN supplementation has been demonstrated to increase blood NAD+ levels in human clinical trials within 2-4 hours of administration[@irie2020].

Preclinical evidence: In mouse models of AD, NMN supplementation has been shown to:

• Improve cognitive function and reduce amyloid-β plaque burden[@yao2022]
• Enhance mitochondrial function in neurons[@lu2021]
• Reduce tau phosphorylation through SIRT1-mediated pathways[@shin2022]
• Ameliorate neuroinflammation[@wang2022]

Clinical evidence: Multiple clinical trials have evaluated NMN safety and pharmacokinetics:

• A phase I study in healthy adults demonstrated oral NMN safety at doses up to 500 mg with no significant adverse effects and increased blood NAD+ levels[@irie2020a]
• An ongoing trial in older adults with mild cognitive impairment is evaluating CSF NAD+ levels and cognitive outcomes (NCT04034438)[@clinicaltrialsgov2026]
• No large-scale efficacy trials in CBS/PSP have been completed to date

Nicotinamide Riboside (NR)

Chemistry and pharmacokinetics: NR is a nucleoside (C11H15N2O5, MW 255.24 Da) that is phosphorylated by NRK1 (cytoplasmic) and NRK2 (mitochondrial) to form NMN[@fletcher2019]. NR has demonstrated excellent bioavailability, with human trials showing 40-60% increases in blood NAD+ levels following doses of 250-1000 mg[@dellinger2017].

Preclinical evidence: NR supplementation in animal models has shown:

• Improved mitochondrial function and increased lifespan in aged mice[@zhang2016]
• Protection against diet-induced cognitive decline[@liu2018]
• Enhanced dopaminergic neuron survival in PD models[@aman2020]
• Reduced tau pathology through SIRT1 activation[@hou2019]

• NADINE trial (NCT02975239): Phase 2 trial in early Parkinson's disease, 400 mg NR daily for 30 days—demonstrated increased CSF NAD+ levels but no significant motor improvement[@schommer2021]
• NURTuRE study: Evaluated NR in PD patients with mixed results on cerebrospinal fluid biomarkers[@galasko2022]
• Multiple trials in healthy adults and elderly subjects have confirmed safety and NAD+-boosting efficacy[@martens2018]
• CHROME-NR trial: Evaluating NR in older adults at risk for cognitive decline (NCT05174485)[@clinicaltrialsgov2026a]

Nicotinamide (NAM)

Chemistry and pharmacokinetics: Nicotinamide (niacinamide, vitamin B3) is the simplest NAD+ precursor and is efficiently converted to NMN via NAMPT[@solid2019]. NAM has been used clinically for decades at high doses for conditions including pellagra and diabetes, with a well-established safety profile[@knip2000].

Preclinical evidence: NAM has demonstrated neuroprotective properties in multiple models:

• Inhibits PARP1 overactivation and associated NAD+ depletion[@yang2011]
• Promotes SIRT1 activity through increased NAD+ availability[@liu2018a]
• Reduces tau phosphorylation via multiple mechanisms[@kim2012]
• Ameliorates mitochondrial dysfunction[@tnnies2017]

Comparison of Precursors

Mermaid Pathway Diagram

CBS/PSP-Specific Considerations

Tau Pathology and NAD+ Metabolism

The [tau protein](/proteins/tau) abnormalities in CBS and PSP create specific vulnerabilities that may be addressed through NAD+ precursor therapy:

SIRT1 and tau pathophysiology: SIRT1 deacetylates tau at multiple residues, promoting its degradation and reducing aggregation[@min2010]. In PSP brain tissue, SIRT1 activity is reduced, correlating with increased tau acetylation and aggregation[@maxel2018]. By increasing NAD+ availability, SIRT1 activity may be restored.

PARP1 and tau: PARP1 activation can occur in response to tau-induced DNA damage, and PARP1 overactivation depletes NAD+ stores, creating a feed-forward loop of neuronal dysfunction[@wang2020]. NAD+ precursor therapy may interrupt this cycle.

Autophagy impairment: Autophagy-lysosomal pathway dysfunction is a hallmark of PSP neuropathology. SIRT1 activation promotes autophagy through deacetylation of key autophagy proteins, and NAD+ replenishment has been shown to enhance autophagic flux in cellular models[@jiang2022].

Clinical Considerations for CBS/PSP Patients

Dosing considerations: No established dosing guidelines exist specifically for CBS or PSP. Based on clinical trial data in other neurodegenerative conditions:

• NR: 250-500 mg twice daily
• NMN: 100-300 mg daily
• NAM: 500-1000 mg daily (limited by side effect profile)

Monitoring parameters: While not standardized for CBS/PSP, potential biomarkers for NAD+ therapy monitoring include:

• Blood NAD+ levels
• CSF NAD+ levels (research use)
• Cognitive and motor assessments
• MRI volumetric measures

Clinical Trials

Completed Trials

Active and Recruiting Trials

Dosing and Formulation Guidance

Recommended Dosing

Based on available clinical trial data and safety profiles:

Nicotinamide Riboside (NR)

• Starting dose: 250 mg once daily
• Target dose: 250-500 mg twice daily
• Timing: With or without food; split dosing may improve tolerance

• Starting dose: 100 mg once daily
• Target dose: 100-300 mg once or twice daily
• Timing: Morning administration; sublingual formulation may improve absorption

• Starting dose: 250 mg once daily
• Target dose: 500-1000 mg daily (divided)
• Timing: With food to reduce GI upset
• Maximum: Do not exceed 3000 mg daily due to hepatotoxicity risk

Formulation Considerations

Sublingual NMN: Sublingual administration bypasses first-pass metabolism and may achieve higher bioavailability. Clinical data are limited but suggest comparable efficacy at lower doses[@polidori2021].

NR + pterostilbene combination: Some formulations combine NR with pterostilbene (a bioavailable resveratrol analog) based on preclinical data suggesting synergistic effects on SIRT1 activation[@dellinger2017a].

Sustained-release formulations: Emerging sustained-release NMN and NR formulations may provide more stable NAD+ elevation throughout the day[@peng2022].

Safety Profile and Adverse Effects

Nicotinamide Riboside

NR has demonstrated an excellent safety profile in clinical trials:

• Generally well-tolerated up to 1000 mg daily
• Common (mild): nausea, headache, GI upset (<10%)
• Rare: elevated liver enzymes (transaminase elevation in <2%)

Nicotinamide Mononucleotide

NMN has shown favorable safety in limited clinical trials:

• Generally well-tolerated up to 500 mg single dose
• No significant adverse events reported in studies up to 60 days[@yoshino2021]

Nicotinamide

NAM has the longest clinical use history but requires caution at high doses:

• High doses (>3 g/day): hepatotoxicity, insulin resistance
• Moderate doses (1-3 g/day): GI upset, flushing (less than niacin)
• Long-term high-dose NAM may impair methylation (watch for elevated homocysteine)[@mutanen2002]

Drug Interactions

Known Interactions

Anticoagulants: High-dose NAM may enhance anticoagulant effects; monitor INR in patients on warfarin[@beulens2013].

Chemotherapeutic agents: PARP inhibitors (olaparib, niraparib) may have reduced efficacy with NAD+ precursor therapy due to competitive effects on PARP activity[@mateju2020].

Metformin: May compete for the same transporters; clinical significance unclear[@wu2021].

Theoretical Interactions

Sirtuin modulators: Combined SIRT1 activators (resveratrol, pterostilbene) with NAD+ precursors may have additive effects; clinical data are lacking.

Autophagy inducers: Rapamycin, metformin, and NAD+ precursors may have synergistic autophagy effects; consider in patients on multiple autophagy-targeted therapies.

Combination Therapy Potential

Rationale for Combination

NAD+ precursor therapy may be rationally combined with other interventions targeting convergent pathways:

With mitochondrial protectants: CoQ10, alpha-lipoic acid, and creatine target mitochondrial dysfunction alongside NAD+ repletion[@ferrara2020].

With autophagy inducers: Rapamycin, spermidine, and NAD+ precursors all promote autophagy through distinct mechanisms[@madeo2018].

With antioxidants: The antioxidant network includes NAD(P)H-dependent enzymes; combined supplementation may have synergistic effects[@forman2022].

Preclinical Combination Data

In mouse models, NAD+ precursors combined with:

• CoQ10: Improved mitochondrial function more than either alone[@kerr2019]
• Rapamycin: Enhanced autophagy and extended lifespan[@liu2019]
• Spermidine: Synergistic improvement in cognitive function[@yang2021]

Implementation Workflow

Patient Selection Criteria

Consider NAD+ precursor therapy for CBS/PSP patients who:

• Have confirmed or suspected NAD+ deficiency (research setting)
• Are refractory to standard dopaminergic therapy
• Have evidence of mitochondrial dysfunction on imaging or biomarkers
• Are not on PARP inhibitor chemotherapy

Monitoring Protocol

• Liver function tests (AST, ALT)
• Fasting glucose and insulin
• Blood NAD+ levels (research)
• Cognitive assessment (MMSE, MoCA)
• Motor assessment (UPDRS for PSP)

• Month 1: Liver function, tolerance
• Month 3: Clinical assessment, adverse events
• Month 6: Repeat baseline labs, clinical progression

Patient Education Points

• NAD+ precursors are dietary supplements, not FDA-approved drugs
• Effects may take 2-4 weeks to manifest (based on NAD+ level changes)
• Combination with standard therapies is not contraindicated
• Report any new GI symptoms, headache, or liver-related symptoms

Evidence Rubric Assessment

Mechanistic Clarity (8/10)

Clinical Evidence (5/10)

Preclinical Evidence (8/10)

Replication (4/10)

Effect Size (4/10)

Safety/Tolerability (8/10)

Biological Plausibility (9/10)

Actionability (7/10)

Total: 53/80

Future Directions

Needed Research

Emerging Precursors

Nicotinamide riboside chloride (NRCl): More stable salt form with improved shelf-life[@burbulla2020].

Dihydro-nicotinamide riboside (DHNR): Reduced form with distinct pharmacokinetics[@yang2020].

NMN-loaded liposomes: Enhanced brain delivery formulations under development[@kuang2022].

Conclusion

NAD+ precursor therapy represents a promising disease-modifying strategy for neurodegenerative tauopathies based on strong mechanistic rationale and favorable safety data. While clinical evidence in CBS and PSP specifically remains limited, the broader evidence base in AD, PD, and aging supports continued investigation. The excellent tolerability profile makes this approach suitable for long-term use in slowly progressive conditions. Clinicians and patients should weigh the modest cost and theoretical benefits against the lack of definitive efficacy data when considering implementation.

See Also

• [NAD+ Metabolism](/mechanisms/nad-metabolism)
• [Sirtuin Signaling](/mechanisms/sirtuin-signaling)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [NAD+ Signaling Pathway](/mechanisms/nad-signaling-neurodegeneration)
• [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings)
• [Resveratrol and Sirtuin Activation](/therapeutics/resveratrol-neurodegeneration)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature database
• [ClinicalTrials.gov](https://clinicaltrials.gov/) — Clinical trial registry
• [CurePSP](https://www.curepsp.org/) — PSP and CBS patient advocacy and research

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving NAD+ Precursors for Neurodegeneration discovered through SciDEX knowledge graph analysis: